Bloomberg BNA Publishes Article Analyzing 2nd Circuit Ruling on Off-Label Drug Promotion

January 24, 2013

Reading Time : 1 min

Contact:

Jacinta O'Shea-Ramdeholl

Director of Communications

Sarah Richmond

Senior Communications Manager

A recent ruling by the U.S. Court of Appeals for the 2nd Circuit regarding the off-label promotion of pharmaceutical drugs was the subject of an article by James Tysse and Patricia Millett, counsel and co-head, respectively, of Akin Gump’s appellate practice, and Mark Mansour, partner in Akin Gump’s food and drug law practice.

“Free Speech and the Future of Off-Label Pharmaceutical Marketing Regulation After United States v. Caronia” addresses how the ruling could affect the Food and Drug Administration’s stance on off-label marketing and whether it would prevent the Department of Justice from bringing future cases against individuals. The article also discusses whether the First Amendment offers enough protections for off-label speech.

Please click here to read the article.

Share This Insight

People Mentioned in This News

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.